Publications by authors named "Tim Wyant"

Claim this Profile
F
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Walter Reinisch, Brian Bressler, Rebecca Curtis, Asit Parikh, Huyuan Yang, Tim Wyant

Inflamm Bowel Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Melissa Gallery, Julie Zhang, Daniel P Bradley, Pamela Brauer, Donna Cvet, Tim Wyant

PLoS One· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Tim Wyant

Clin Pharmacokinet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Tim Wyant, Eric Fedyk, Brihad Abhyankar

J Crohns Colitis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Khaldoun Almhanna, Thea Kalebic, Cristina Cruz, Jason E Faris, David P Ryan, Tim Wyant

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
Tim Wyant, Jose Estevam, Lili Yang, Maria Rosario

Cytometry B Clin Cytom· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
Tim Wyant, Tim Leach, Serap Sankoh, Yuemei Wang, Jonathan Paolino

Gut· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
Catherine Milch, Tim Wyant, Jing Xu, Asit Parikh, Whitney Kent

J Neuroimmunol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, Tim Wyant

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.
Krista G Haanstra, Sam O Hofman, Dave M Lopes Estêvão, Erwin L A Blezer, Jan Bauer, Tim Wyant

J Immunol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.
Eric R Fedyk, Tim Wyant, Li-Li Yang, Vilmos Csizmadia, Kristine Burke

Inflamm Bowel Dis· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.
Asit Parikh, Timothy Leach, Tim Wyant, Catherine Scholz, Serap Sankoh

Inflamm Bowel Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis.
Maria C Lebre, Clarissa E Vergunst, Ivy Y K Choi, Saïda Aarrass, Ana S F Oliveira, Tim Wyant

PLoS One· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region.
Jim Gilbert, Julie Lekstrom-Himes, Debra Donaldson, Yih Lee, Mingxiu Hu, Tim Wyant

Am J Cardiol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
Clarissa E Vergunst, Danielle M Gerlag, Lisa von Moltke, Michael Karol, Tim Wyant

Arthritis Rheum· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Dulce Soler, Tobias Chapman, Li-Li Yang, Tim Wyant, Robert Egan

J Pharmacol Exp Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis